Clark Capital Management Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.2M Buy
231,956
+17,854
+8% +$1.22M 0.1% 164
2026
Q1
$13.8M Buy
214,102
+70,216
+49% +$4.95M 0.09% 166
2025
Q4
$9.68M Sell
143,886
-59,079
-29% -$3.97M 0.06% 168
2025
Q3
$14.9M Buy
202,965
+25,582
+14% +$1.7M 0.09% 151
2025
Q2
$9.23M Sell
177,383
-28,379
-14% -$1.61M 0.06% 160
2025
Q1
$13.1M Buy
205,762
+26,935
+15% +$1.56M 0.09% 148
2024
Q4
$8.55M Buy
178,827
+41,655
+30% +$2.14M 0.06% 162
2024
Q3
$7.85M Buy
137,172
+34,247
+33% +$1.96M 0.05% 162
2024
Q2
$5.39M Buy
+102,925
New +$4.51M 0.04% 171
2023
Q2
– Sell
-29,636
Closed -$1.13M – 350
2023
Q1
$1.13M Sell
29,636
-4,987
-14% -$234K 0.01% 247
2022
Q4
$1.97M Buy
34,623
+1,019
+3% +$52.2K 0.02% 216
2022
Q3
$1.33M Sell
33,604
-162
-0.5% -$7.16K 0.02% 236
2022
Q2
$1.49M Buy
+33,766
New +$1.46M 0.02% 217
2022
Q1
– Sell
-55,222
Closed -$2.22M – 376
2021
Q4
$2.22M Sell
55,222
-2,651
-5% -$99K 0.03% 215
2021
Q3
$2.35M Buy
+57,873
New +$2.42M 0.03% 212

Other funds holding HALO

Clark Capital Management Group's HALO Position: Q2 2026 in Review

Clark Capital Management Group increased its Halozyme (HALO) stake by 8.3% in Q2 2026, buying an estimated $1.22M and bringing the position to 231,956 shares worth $18.2M. The position accounts for 0.1% of the portfolio, ranked #164.

Clark Capital Management Group first reported a position in HALO in Q3 2021 and has held it in 15 quarters since. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Clark Capital Management Group held 231,956 shares of Halozyme worth $18.2M as of Q2 2026.
  • Clark Capital Management Group bought 17,854 Halozyme shares in Q2 2026, an estimated $1.22M.
  • Halozyme made up 0.1% of Clark Capital Management Group's portfolio in Q2 2026, its #164 holding.
  • Clark Capital Management Group first reported a position in Halozyme in Q3 2021 and has held it in 15 quarters since.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.